Summary
The alkylating agent Hepsulfam (Sulfamic acid 1,7-heptanediyl ester, NSC 329680) was developed as a more hydrophilic analog of busulfan. The objective of this study was to determine partitioning of hepsulfam between blood, plasma, and cerebrospinal fluid (CSF) in two female baboons following intravenous administration. Hepsulfam was administered at 11 mg/kg, and blood and CSF levels were determined by gas chromatography with electron capture detection. Blood levels were fairly constant btween animals (17–25 and 20–23 μg/ml) for six hours after administration, following peak levels of 43 and 33 μg/ml, respectively, for the two animals. Peak plasma levels of 35 and 36 μg/ml were achieved, and initial plasma half-lives in babbons were similar to those seen in other species, with at1/2 α of 1 h. The plasma terminal half life of 0.2 h, estimated from limited sampling times, was shorter in baboons than in mice, dogs, or humans. Baboon CSF levels decreased from 1.7 to 0.3 μg/ml during 6h post infusion, and peak concentrations in CSF lagged behind plasma levels. CSF/plasma ratios ranged from 0.33 to 0.62 in one animal, whereas ratios of 0.2–0.25 were maintained in the other animal during the same period. Results from this study indicate hepsulfam will enter the CSF following intravenous administration, and the CSF/plasma ratios are lower than those obtained following oral busulfan administration.
Similar content being viewed by others
References
Brodfuehrer JI, Powis G: Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC329680) and its stability in buffer, blood, and plasma. J Chromatogr 427:247–255, 1988
Bisschop JB, Wassom JS: Toxicological review of busulfan (Myleran), Mutat Res 168:15–45, 1986
Santos GW, Tutshka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart PK, Yeager AM: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 309:1347–1353, 1983
Vodopick H, Hamilton HE, Jackson HL, Peng CT, Sheets RF: Metabolic fate of tritiated busulfan in man. J Lab and Clin Med 73:266–276, 1969
Hassan M, Öberg G, Ehrsson H, Ehrnebo M, Smedmyr B, Tötterman T, Eksborg S, Simonson B: Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 26:525–530, 1989
Vassal G, Re M, Gouyette A: Gas chromatographic-mass spectrometry assay for busulfan in biological fluids using a deuterated internal standard. J Chromatrogr Biomed Appl 428:357–361, 1988
Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugières L, Kalifam G, Gouyette A, Lemerle J: Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study. Cancer Res 50:6203–6207, 1990.
Vassal G, Gouyette A, Hartmann A, Pico JL, Lemerle J: Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24:386–390, 1989
Hassan M, Ehrsson H, Smedmyr B, Tötterman T, Wallin I, Öberg G, Simonsson B: Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplantation 4:113–114, 1989
Brodfuehrer JI, Wilke TJ, Powis G: Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. Cancer Chemother Pharmacol 22:120–125, 1988
Ravdin PM, Havlin KA, Marshall MV, Brown TD, Koeller JM, Kuhn JG, Rodriguez G, Von Hoff DD: A phase I clinical and pharmacokinetic trial of hepsulfam. Cancer Res. 51:6268–6272, 1991
Hendricks CB, Grochow LB, Rowinsky EK, Forastiere AA, McGuire WP, Ettinger DS, Sartorius S, Lubejko B, Donehower R: Phase I clinical and pharmacokinetic trials of hepsulfam (NSC 329680). Cancer Res. 51:5781–5785, 1991
Pacheco DY, Stratton NK, Gibson NW: Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line. Cancer Res 49:5108–5110, 1989
Marshall MV, Marshall MH, Degen DR, Roodman GD, Kuhn JG, Ross ME, Von Hoff DD:In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units. Stem Cells 11:62–69, 1993
Waud WR, Plowman J, Paull KD, Narayanan VL, Bailey DM, Harrison SD, Dykes DJ, Laster WR, Griswold DP: Preclinical antitumor activity of hepsulfam (NSC-329680). Proc. Am Assn Cancer Res 29:1323, 1988
Berger DP, Winterhalter BR, Dengler WA, Fiebig H-H: Preclinical activity of hepsulfam and busulfan insolid human tumor xenografts and human bone marrow. Anti-Cancer Drugs 3:531–539, 1992
Du D-L, Volpe DA, Grieshaber CK, Murphy Jr MJ: Comparative toxicity of fostreicin, hepsulfam and pyrazine diazohydroxide to human hematopoietic progenitor cellsin vitro. Invest New Drugs 9:149–157, 1991
Pacheco DY, Cook C, Hinks JR, Gibson NW: Mechanisms of toxicity of hepsulfam in human tumor cell lines. Cancer Res 50:7555–7558, 1990
Hinks JR, Adlakha A, Cook CA, Johnson CS, Furmanski P, Gibson NW:In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients. Cancer Res 50:7559–7563, 1990
Geller RB, Janisch L, Kampmeier P, Ratain MJ: Phase I trial of hepsulfam in patients (pts) with refractory leukemia. Proc Soc Am Assn Cancer Res 11:264, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marshall, M.V., Carey, K.D., Von Hoff, D.D. et al. Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons. Invest New Drugs 13, 33–36 (1995). https://doi.org/10.1007/BF02614217
Issue Date:
DOI: https://doi.org/10.1007/BF02614217